Voyager Therapeutics, Inc. (VYGR)

7,62 +0,20 (+2,70 %) À la clôture : 04:00PM EDT

Voyager Therapeutics, Inc.

75 Hayden Avenue
Lexington, MA 02421
United States
857 259 5340
https://www.voyagertherapeutics.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 162

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.	President, CEO & Director	1,01M	S.O.	1958
Ms. Robin Swartz	COO, Principal Financial & Accounting Officer and Acting Chief Business Officer	661,98k	S.O.	1971
Ms. Jacquelyn Fahey Sandell Esq., J.D.	Chief Legal Officer	538,16k	S.O.	1971
Dr. Krystof Bankiewicz M.D., Ph.D.	Founder	S.O.	S.O.	S.O.
Dr. Guangping Gao Ph.D.	Founder & Member of Scientific Advisory Board	S.O.	S.O.	S.O.
Dr. Mark A. Kay M.D., Ph.D.	Founder	S.O.	S.O.	1959
Dr. Phillip D. Zamore Ph.D.	Founder & Member of Scientific Advisory Board	S.O.	S.O.	S.O.
Mr. Todd Carter Ph.D.	Chief Scientific Officer	S.O.	S.O.	1970
Ms. Michelle Quinn Smith	Chief Human Resources Officer	S.O.	S.O.	S.O.
Dr. Maria Lopez-Bresnahan M.B.A., M.D.	Senior Vice President of Translational Medicine & Clinical Development	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Voyager Therapeutics, Inc. en date du 1 avril 2024 est 7. Les scores principaux sont Audit : 3; Société : 6; Droits des actionnaires : 8; Compensation : 8.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.